OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 okt 2010 - 14:30
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces publication of key Phase IIb results for Locteron which confirm Locteron's improved tolerability up to 60 weeks into the SELECT-2 study
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its licensee Biolex Therapeutics today has published positive interim results at week 60 of the Phase IIb trial, 12 weeks after completion of 48 weeks of treatment with Locteron®. The results are consistent with the existing clinical results for Locteron and confirm Locteron’s improved tolerability profile.
Simon Sturge, CEO of OctoPlus, says: “These positive results further demonstrate the value of our PolyActive® technology and show that Locteron’s targeted benefits are sustained in the long term, up to 12 weeks after the end of treatment. Based on increasing evidence we believe that interferon alpha will remain a core component of future hepatitis C treatment regimens, and these positive results position Locteron as a key product in hepatitis C therapy.“
Datum laatste update: 29 december 2025